Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.65 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053523 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL17112600 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL14222418 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL649983 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL17112575 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL1394716 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL31128136 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL17112628 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL19741915 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Bicarbonate SCHEMBL9225058 | 0.96 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924217-A | 5-HTT/HDAC dual inhibitor and preparation method and application thereof | 杭州师范大学 | 2024-04-26 | — | — | CN | claimed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122059867-A | Substituted indole compounds, preparation method and application thereof | 安徽医科大学 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| CN-1137273-A | Quinolizinone type compounds | ABBOTT LAB (US) | 1996-12-04 | — | — | CN | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBP, EBPL, ELP1 | CHRNB2 2145/4885CHRNA4 1506/4885CHRNB4 1266/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | CHRNB2 1090/4885CHRNA4 1672/4885CHRNB4 1152/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | CHRNB2 63/4885CHRNA4 11/4885CHRNB4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.